Cochrane Review Group
Eyes and Vision
171 systematic reviews in Eyes and Vision ask 2,112 questions. 27.8% have no studies to answer them, 21.1% rest on very low certainty evidence and 20.2% reach moderate or high certainty.
Reviews
171
Questions
2,112
current versions
No studies
27.8%
Moderate or high
20.2%
No studies 587 · 27.8%Ungraded 95 · 4.5%Very low 446 · 21.1%Low 557 · 26.4%Moderate 361 · 17.1%High 66 · 3.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Thinnest evidence
All no studies and very low questions| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
LipiFlow vs basic warm compresses Mean change from baseline in symptom scores at 1 to 4 weeks (lower is favored) · people with dry eye LipiFlow for the treatment of dry eye disease (2024) · Cochrane | no estimate extracted | NR | Very low |
LipiFlow vs thermostatic devices Proportion of participants with intervention‐related, vision‐threatening adverse events at 1 to 4 weeks · people with dry eye LipiFlow for the treatment of dry eye disease (2024) · Cochrane | no estimate extracted | 4 studies · 445 participants | Very low |
LipiFlow vs basic warm compresses Mean change from baseline in meibomian gland expression scores at 1 to 4 weeks (higher is favored) · people with dry eye LipiFlow for the treatment of dry eye disease (2024) · Cochrane | SMD 1.31 | 2 studies · 76 participants | Very low |
LipiFlow vs basic warm compresses Mean change from baseline in meibum quality scores at 1 to 4 weeks (higher is favored) · people with dry eye LipiFlow for the treatment of dry eye disease (2024) · Cochrane | no estimate extracted | 1 study · 46 participants | Very low |
LipiFlow vs thermostatic devices Mean change from baseline in symptom scores at 1 to 4 weeks (lower is favored) · people with dry eye LipiFlow for the treatment of dry eye disease (2024) · Cochrane | no estimate extracted | NR | Very low |
Face‐down positioning vs other positioning Proportion of eyes with retinal displacement at 6 months or later (RR < 1 favored) · people with primary macula‐involving rhegmatogenous retinal detachments Face‐down positioning or posturing after pars plana vitrectomy for macula‐involving rhegmatogenous retinal… (2024) · Cochrane | RR 0.73 [0.54, 0.99] | 1 study · 239 participants | Very low |
Face‐down positioning vs other positioning Mean change in logMAR or Snellen visual acuity from baseline to 3 months or later (lower is favored) · people with primary macula‐involving rhegmatogenous retinal detachments Face‐down positioning or posturing after pars plana vitrectomy for macula‐involving rhegmatogenous retinal… (2024) · Cochrane | no estimate extracted | 1 study · 56 participants | Very low |
Face‐down positioning vs other positioning Mean objective distortion score at 3 months or later (lower is favored) · people with primary macula‐involving rhegmatogenous retinal detachments Face‐down positioning or posturing after pars plana vitrectomy for macula‐involving rhegmatogenous retinal… (2024) · Cochrane | MD 1.8 | 1 study · 219 participants | Very low |
Face‐down positioning vs other positioning Quality of life assessments at 3 months or later (higher is favored) · people with primary macula‐involving rhegmatogenous retinal detachments Face‐down positioning or posturing after pars plana vitrectomy for macula‐involving rhegmatogenous retinal… (2024) · Cochrane | no estimate extracted | 1 study · 217 participants | Very low |
Face‐down positioning vs other positioning Frequency of intervention‐related ocular adverse events ( · people with primary macula‐involving rhegmatogenous retinal detachments Face‐down positioning or posturing after pars plana vitrectomy for macula‐involving rhegmatogenous retinal… (2024) · Cochrane | no estimate extracted | 1 study · 262 participants | Very low |
Face‐down positioning vs other positioning Frequency of intervention‐related non‐ocular adverse events ( · people with primary macula‐involving rhegmatogenous retinal detachments Face‐down positioning or posturing after pars plana vitrectomy for macula‐involving rhegmatogenous retinal… (2024) · Cochrane | no estimate extracted | NR | No studies |
Lutein with or without zeaxanthin vs placebo Adverse effects · people with AMD Antioxidant vitamin and mineral supplements for slowing the progression of age‐related macular degeneration (2023) · Cochrane | OR 1.06 | NR | Very low |
Reviews 171
Interventions to improve access to cataract surgical services and their impact on equity in low‐ and middle‐income countries
CochraneSoF table
14 questions
Ocriplasmin for symptomatic vitreomacular adhesion
CochraneSoF table
7 questions
Topical treatments for blepharokeratoconjunctivitis in children
CochraneSoF table
7 questions
Surgical interventions for vertical strabismus in superior oblique palsy
CochraneSoF table
14 questions
Antibiotics versus no treatment for toxoplasma retinochoroiditis
CochraneSoF table
5 questions
Multifocal versus monofocal intraocular lenses after cataract extraction
CochraneSoF table
7 questions
Patching for corneal abrasion
CochraneSoF table
8 questions
Prophylactic non‐steroidal anti‐inflammatory drugs for the prevention of macular oedema after cataract surgery
CochraneSoF table
14 questions
Statins for age‐related macular degeneration
CochraneSoF table
3 questions
Oral antivirals for preventing recurrent herpes simplex keratitis in people with corneal grafts
CochraneSoF table
4 questions
Over the counter (OTC) artificial tear drops for dry eye syndrome
CochraneSoF table
31 questions
Anti‐vascular endothelial growth factor for control of wound healing in glaucoma surgery
CochraneSoF table
7 questions
Laser‐assisted subepithelial keratectomy (LASEK) versus photorefractive keratectomy (PRK) for correction of myopia
CochraneSoF table
6 questions
Integrated versus non‐integrated orbital implants for treating anophthalmic sockets
CochraneSoF table
4 questions
Doxycycline plus ivermectin versus ivermectin alone for treatment of patients with onchocerciasis
CochraneSoF table
6 questions
Anti‐vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia
CochraneSoF table
7 questions
Fibrin glue versus sutures for conjunctival autografting in primary pterygium surgery
CochraneSoF table
3 questions
Aflibercept for neovascular age‐related macular degeneration
CochraneSoF table
6 questions
Conjunctival autograft for pterygium
CochraneSoF table
7 questions
Valacyclovir versus acyclovir for the treatment of herpes zoster ophthalmicus in immunocompetent patients
CochraneSoF table
7 questions
Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis
CochraneSoF table
28 questions
Medical interventions for fungal keratitis
CochraneSoF table
6 questions
Mitomycin C versus 5‐Fluorouracil for wound healing in glaucoma surgery
CochraneSoF table
7 questions
Laser treatment of drusen to prevent progression to advanced age‐related macular degeneration
CochraneSoF table
7 questions
Combined surgery versus cataract surgery alone for eyes with cataract and glaucoma
CochraneSoF table
5 questions